clopidogrel + ticagrelor

Clopidogrel + ticagrelor is a combination of two oral antiplatelet agents used in cardiovascular medicine. Both drugs are P2Y12 receptor antagonists but differ in their pharmacology. Clopidogrel is a thienopyridine prodrug that irreversibly inhibits the platelet P2Y12 ADP receptor after metabolic activation, leading to reduced platelet aggregation. Ticagrelor is a cyclopentyltriazolopyrimidine that directly and reversibly inhibits the same receptor without requiring metabolic activation. Both are primarily indicated for prevention of thrombotic events such as myocardial infarction and stroke in patients with acute coronary syndromes (ACS) or those undergoing percutaneous coronary intervention (PCI). The combination of these two agents together is not standard clinical practice due to increased bleeding risk; typically only one P2Y12 inhibitor is used at a time alongside aspirin as part of dual antiplatelet therapy[3][4][8]. There are no established guidelines or approved indications for using both drugs simultaneously.

Brand names

BrilintaBriliquePlavix

Other names

clopidogrel bisulfateAZD6140AZD-6140AZD 6140